Search research articles
Contact Us
Filters
Showing results (11-20 of 34) with videos related to
Page
of 4
Sort By:
Antimicrobial Agents and Chemotherapy
|
April 11, 2013
Severe skin toxicity in pediatric oncology patients treated with voriconazole and concomitant methotrexate
Johan G C van Hasselt, Natasha K A van Eijkelenburg, Alwin D R Huitema, et al.
British Journal of Clinical Pharmacology
|
March 6, 2026
Pharmacokinetics and pharmacodynamics of intravenous and oral (S)-ketamine: Investigating metabolite contribution to subjective effects
Marije E Otto, Gabriël E Jacobs, Joost C van Mechelen, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making
|
March 22, 2013
Development of a framework for cohort simulation in cost-effectiveness analyses using a multistep ordinary differential equation solver algorithm in R
Gerardus W J Frederix, Johan G C van Hasselt, Johan L Severens, et al.
Pharmacoeconomics
|
November 23, 2013
The impact of structural uncertainty on cost-effectiveness models for adjuvant endocrine breast cancer treatments: the need for disease-specific model standardization and improved guidance
Gerardus W J Frederix, Johan G C van Hasselt, Jan H M Schellens, et al.
Journal of Pharmacokinetics and Pharmacodynamics
|
October 19, 2022
A system pharmacology Boolean network model for the TLR4-mediated inflammatory response in early sepsis
Feiyan Liu, Linda B S Aulin, Sebastiaan S A Kossen, et al.
Clinical Pharmacokinetics
|
March 9, 2022
Pooled Population Pharmacokinetic Analysis for Exploring Ciprofloxacin Pharmacokinetic Variability in Intensive Care Patients
Tingjie Guo, Alan Abdulla, Birgit C P Koch, et al.
British Journal of Clinical Pharmacology
|
January 3, 2013
Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans
Linda E Klumpers, Christine Roy, Geraldine Ferron, et al.
British Journal of Clinical Pharmacology
|
June 12, 2012
Novel Δ(9) -tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects
Linda E Klumpers, Tim L Beumer, Johan G C van Hasselt, et al.
Clinical Pharmacokinetics
|
June 10, 2011
Lidocaine (lignocaine) dosing regimen based upon a population pharmacokinetic model for preterm and term neonates with seizures
Marcel P H van den Broek, Alwin D R Huitema, Johan G C van Hasselt, et al.
Journal of Clinical and Translational Science
|
August 23, 2021
Zebrafish larvae as experimental model to expedite the search for new biomarkers and treatments for neonatal sepsis
Fleur M Keij, Bjørn E V Koch, Fernando Lozano Vigario, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 34) with videos related to
Sort By:
Page
of 4
Antimicrobial Agents and Chemotherapy
|
April 11, 2013
Severe skin toxicity in pediatric oncology patients treated with voriconazole and concomitant methotrexate
Johan G C van Hasselt, Natasha K A van Eijkelenburg, Alwin D R Huitema, et al.
British Journal of Clinical Pharmacology
|
March 6, 2026
Pharmacokinetics and pharmacodynamics of intravenous and oral (S)-ketamine: Investigating metabolite contribution to subjective effects
Marije E Otto, Gabriël E Jacobs, Joost C van Mechelen, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making
|
March 22, 2013
Development of a framework for cohort simulation in cost-effectiveness analyses using a multistep ordinary differential equation solver algorithm in R
Gerardus W J Frederix, Johan G C van Hasselt, Johan L Severens, et al.
Pharmacoeconomics
|
November 23, 2013
The impact of structural uncertainty on cost-effectiveness models for adjuvant endocrine breast cancer treatments: the need for disease-specific model standardization and improved guidance
Gerardus W J Frederix, Johan G C van Hasselt, Jan H M Schellens, et al.
Journal of Pharmacokinetics and Pharmacodynamics
|
October 19, 2022
A system pharmacology Boolean network model for the TLR4-mediated inflammatory response in early sepsis
Feiyan Liu, Linda B S Aulin, Sebastiaan S A Kossen, et al.
Clinical Pharmacokinetics
|
March 9, 2022
Pooled Population Pharmacokinetic Analysis for Exploring Ciprofloxacin Pharmacokinetic Variability in Intensive Care Patients
Tingjie Guo, Alan Abdulla, Birgit C P Koch, et al.
British Journal of Clinical Pharmacology
|
January 3, 2013
Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans
Linda E Klumpers, Christine Roy, Geraldine Ferron, et al.
British Journal of Clinical Pharmacology
|
June 12, 2012
Novel Δ(9) -tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects
Linda E Klumpers, Tim L Beumer, Johan G C van Hasselt, et al.
Clinical Pharmacokinetics
|
June 10, 2011
Lidocaine (lignocaine) dosing regimen based upon a population pharmacokinetic model for preterm and term neonates with seizures
Marcel P H van den Broek, Alwin D R Huitema, Johan G C van Hasselt, et al.
Journal of Clinical and Translational Science
|
August 23, 2021
Zebrafish larvae as experimental model to expedite the search for new biomarkers and treatments for neonatal sepsis
Fleur M Keij, Bjørn E V Koch, Fernando Lozano Vigario, et al.
Page
of 4